Download PDF
Thromb Haemost 2024; 124(02): 149-151
DOI: 10.1055/s-0043-1776900
Invited Editorial Focus

NOACs in Atrial Fibrillation Patients with Polypharmacy

Bernadette Corica
1   Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
2   Department of Translational and Precision Medicine, Sapienza—University of Rome, Rome, Italy
,
Giulio Francesco Romiti 
1   Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
2   Department of Translational and Precision Medicine, Sapienza—University of Rome, Rome, Italy
,
Marco Proietti 
3   Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
4   Division of Subacute Care, IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy
› Author Affiliations
› Further Information
    Permissions and Reprints




Publication History

Received: 23 October 2023

Accepted: 24 October 2023

Article published online:
21 November 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

Comment to this article:

The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial FibrillationThromb Haemost 2024; 124(02): 135-148
DOI: 10.1055/s-0043-1769735

 

  • References

  • 1 Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017; 17 (01) 230
    CrossrefPubMedGoogle Scholar
  • 2 Delara M, Murray L, Jafari B. et al. Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis. BMC Geriatr 2022; 22 (01) 601
    CrossrefPubMedGoogle Scholar
  • 3 Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 2014; 13 (01) 57-65
    CrossrefPubMedGoogle Scholar
  • 4 Palmer K, Villani ER, Vetrano DL. et al; European Geriatric Medicine Society Pharmacology special interest group. Association of polypharmacy and hyperpolypharmacy with frailty states: a systematic review and meta-analysis. Eur Geriatr Med 2019; 10 (01) 9-36
    CrossrefPubMedGoogle Scholar
  • 5 Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: a systematic review and meta-analysis. J Am Pharm Assoc (2003) 2017; 57 (06) 729-738.e10
    CrossrefPubMedGoogle Scholar
  • 6 Corazza GR, Formagnana P, Lenti MV. Bringing complexity into clinical practice: an internistic approach. Eur J Intern Med 2019; 61: 9-14
    CrossrefPubMedGoogle Scholar
  • 7 Romiti GF, Proietti M, Bonini N. et al; GLORIA-AF Investigators. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase II and III. Thromb Haemost 2022; 122 (12) 2030-2041
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Romiti GF, Proietti M, Vitolo M. et al; ESC-EHRA EORP-AF General Long-Term Registry Investigators. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry. BMC Med 2022; 20 (01) 326
    CrossrefPubMedGoogle Scholar
  • 9 Proietti M, Vitolo M, Harrison SL. et al; ESC-EHRA EORP-AF Long-Term General Registry Investigators. Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. BMC Med 2021; 19 (01) 256
    CrossrefPubMedGoogle Scholar
  • 10 Rochon PA, Petrovic M, Cherubini A. et al. Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens. Lancet Healthy Longev 2021; 2 (05) e290-e300
    CrossrefPubMedGoogle Scholar
  • 11 Pasina L, Brucato AL, Falcone C. et al. Medication non-adherence among elderly patients newly discharged and receiving polypharmacy. Drugs Aging 2014; 31 (04) 283-289
    CrossrefPubMedGoogle Scholar
  • 12 Gallagher C, Nyfort-Hansen K, Rowett D. et al. Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis. Open Heart 2020; 7 (01) e001257
    CrossrefPubMedGoogle Scholar
  • 13 Gorog DA, Gue YX, Chao TF. et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific Expert Consensus Paper. Thromb Haemost 2022; 122 (10) 1625-1652
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Eggebrecht L, Nagler M, Göbel S. et al. Relevance of polypharmacy for clinical outcome in patients receiving vitamin K antagonists. J Am Geriatr Soc 2019; 67 (03) 463-470
    CrossrefPubMedGoogle Scholar
  • 15 Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L, Haemost T. The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Thromb Haemost 2024; 124 (02) 135-148
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Jaspers Focks J, Brouwer MA, Wojdyla DM. et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ 2016; 353: i2868
    CrossrefPubMedGoogle Scholar
  • 17 Piccini JP, Hellkamp AS, Washam JB. et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation 2016; 133 (04) 352-360
    CrossrefPubMedGoogle Scholar
  • 18 Zheng Y, Li S, Liu X, Lip GYH, Guo L, Zhu W. Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis. Thromb Haemost 2023; (e-pub ahead of print) DOI: 10.1055/S-0043-1770724.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Kim DH, Pawar A, Gagne JJ. et al. Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation : a cohort study. Ann Intern Med 2021; 174 (09) 1214-1223
    CrossrefPubMedGoogle Scholar
  • 20 Proietti M, Romiti GF, Vitolo M. et al; ESC-EHRA EORP-AF General Long-Term Registry Investigators. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe. Age Ageing 2022; 51 (08) afac192
    CrossrefPubMedGoogle Scholar
  • 21 Proietti M, Romiti GF, Raparelli V. et al. Frailty prevalence and impact on outcomes in patients with atrial fibrillation: a systematic review and meta-analysis of 1,187,000 patients. Ageing Res Rev 2022; 79: 101652
    CrossrefPubMedGoogle Scholar
  • 22 Martínez-Montesinos L, Rivera-Caravaca JM, Agewall S. et al. Polypharmacy and adverse events in atrial fibrillation: main cause or reflection of multimorbidity?. Biomed Pharmacother 2023; 158: 114064
    CrossrefPubMedGoogle Scholar
  • 23 Bonde AN, Staerk L, Lee CJY. et al. Outcomes among patients with atrial fibrillation and appropriate anticoagulation control. J Am Coll Cardiol 2018; 72 (12) 1357-1365
    CrossrefPubMedGoogle Scholar
  • 24 Chao TF, Joung B, Takahashi Y. et al. 2021 Focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: executive summary. Thromb Haemost 2022; 122 (01) 20-47
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Krittayaphong R, Treewaree S, Wongtheptien W, Kaewkumdee P, Lip GYH. Clinical phenotype classification to predict risk and optimize the management of patients with atrial fibrillation using the Atrial fibrillation Better Care (ABC) pathway: a report from the COOL-AF registry. QJM 2023; hcad219
    CrossrefPubMedGoogle Scholar